Given that dysregulation of multiple GPCRs in CSCs is a common phenomenon not only in HER2+ breast cancer but also other cancers and breast cancer subtypes [16,17], our findings may have important implications for novel approaches that target GPCRs as a new way to eradicate CSCs. This evidence concerns the gene ERBB2 and breast carcinoma.